A rheumatologist & lupus expert reviews lupus nephritis treatment, questioning proteinuria cutoffs & ACR guidelines, advocating for newer therapies & end-of-treatment biopsies.
10 Things to Know about Lupus
SLE treatment is rapidly evolving as new therapies are developed & approved. Here are 10 key insights for clinicians.
Cardiovascular Risks Similar for JAK Inhibitors & bDMARDs
Using data from registries across Europe and Canada, Aymon et al. did not observe an increased incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase (JAK) inhibitors compared with those treated with other biologic disease-modifying anti-rheumatic drugs. Their findings support similar cardiovascular risk profiles for JAK and tumor necrosis factor inhibitors.
How the Experts Treat Sjögren’s Disease
With no FDA-approved drugs for Sjögren’s disease, experts share strategies for managing fatigue, arthritis, dryness, and systemic issues.
Sjögren’s Dry Eye Requires Collaboration Among Eye Doctors, Rheumatologists
Sjögren’s dry eye requires collaboration between rheumatologists and ophthalmologists for optimal patient management and treatment of this quality-of-life issue.
Dazodalibep for Sjögren’s Disease
St.Clair et al. found that patients with Sjögren’s disease treated with dazodalibep experienced greater improvement in key symptoms of dryness, fatigue & pain than patients who received placebo.
Small Fiber Neuropathy: What the Rheumatologist Needs to Know
An expert on peripheral neuropathy shares his practical approach to the diagnosis & management of small fiber neuropathy
New Discoveries in Sjögren’s Disease Hold Promise
This article discusses advances in the diagnosis & treatment of Sjögren’s disease, as well as practical diagnostic tips for clinicians.
New FDA Label Requirements for Opioids
After reviewing data from post-marketing observational studies, the FDA has issued new labeling requirements for opioids with the goal of emphasizing and explaining the risks associated with long-term use.
Promising Phase 2 Results for Efgartigimod alfa-fcab in Adults with Primary Sjögren’s Disease
A study from Peene et al. found that patients with primary Sjögren’s disease experienced significant improvements in systemic disease activity and symptoms when treated with intravenous efgartigimod alfa-fcab.
- 1
- 2
- 3
- …
- 125
- Next Page »